HUP0300566A3 - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents
A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's diseaseInfo
- Publication number
- HUP0300566A3 HUP0300566A3 HU0300566A HUP0300566A HUP0300566A3 HU P0300566 A3 HUP0300566 A3 HU P0300566A3 HU 0300566 A HU0300566 A HU 0300566A HU P0300566 A HUP0300566 A HU P0300566A HU P0300566 A3 HUP0300566 A3 HU P0300566A3
- Authority
- HU
- Hungary
- Prior art keywords
- galantamine
- alzheimer
- disease
- treatment
- behaviour associated
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229960003980 galantamine Drugs 0.000 title 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0300566A2 HUP0300566A2 (hu) | 2003-06-28 |
| HUP0300566A3 true HUP0300566A3 (en) | 2004-10-28 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300566A HUP0300566A3 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (hu) |
| JP (1) | JP2003528913A (hu) |
| KR (1) | KR20020086911A (hu) |
| CN (1) | CN1430514A (hu) |
| AU (2) | AU6584401A (hu) |
| BG (1) | BG107093A (hu) |
| BR (1) | BR0109770A (hu) |
| CA (1) | CA2310926C (hu) |
| CZ (1) | CZ20023543A3 (hu) |
| EE (1) | EE200200554A (hu) |
| HR (1) | HRP20020778A2 (hu) |
| HU (1) | HUP0300566A3 (hu) |
| IL (1) | IL152061A0 (hu) |
| MX (1) | MXPA02009777A (hu) |
| NO (1) | NO20024746L (hu) |
| PL (1) | PL361272A1 (hu) |
| RU (1) | RU2002129298A (hu) |
| SK (1) | SK15422002A3 (hu) |
| WO (1) | WO2001074339A2 (hu) |
| ZA (1) | ZA200207935B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| BRPI0412919A (pt) | 2003-07-25 | 2006-09-26 | Hoffmann La Roche | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| MX2010010460A (es) | 2008-03-27 | 2010-12-15 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| EP3297632A4 (en) * | 2015-05-18 | 2019-01-16 | Synaptec Development LLC | GALANTAMINE ELIMINATION OF AMYLOIDSS |
| WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| HUP0104778A3 (en) * | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL361272A1 (en) | 2004-10-04 |
| EP1272192A2 (en) | 2003-01-08 |
| BG107093A (bg) | 2003-06-30 |
| AU2001265844B2 (en) | 2005-04-14 |
| MXPA02009777A (es) | 2003-03-27 |
| AU6584401A (en) | 2001-10-15 |
| KR20020086911A (ko) | 2002-11-20 |
| BR0109770A (pt) | 2003-02-04 |
| NO20024746D0 (no) | 2002-10-02 |
| CZ20023543A3 (cs) | 2003-03-12 |
| CA2310926A1 (en) | 2000-10-04 |
| JP2003528913A (ja) | 2003-09-30 |
| ZA200207935B (en) | 2004-01-30 |
| EE200200554A (et) | 2004-04-15 |
| RU2002129298A (ru) | 2004-03-27 |
| HRP20020778A2 (en) | 2004-04-30 |
| IL152061A0 (en) | 2003-05-29 |
| NO20024746L (no) | 2002-11-28 |
| SK15422002A3 (sk) | 2003-04-01 |
| WO2001074339A2 (en) | 2001-10-11 |
| CN1430514A (zh) | 2003-07-16 |
| HUP0300566A2 (hu) | 2003-06-28 |
| CA2310926C (en) | 2002-10-15 |
| WO2001074339A3 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL153214A0 (en) | Compounds to treat alzheimer's disease | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| EP1043991A4 (en) | TREATMENT OF ALZHEIMER DISEASE | |
| AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
| HUP0103838A3 (en) | Alzheimer's disease secretase | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| SI1303272T1 (sl) | Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni | |
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| IL155191A0 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
| AU6584401A (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| HUP9903213A3 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease | |
| GB0011410D0 (en) | Therapeutic combination for treating Alzheimer's disease | |
| AU2003303141A8 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| ZA962715B (en) | Pharmaceutical agents for the treatment of Alzheimer's disease. | |
| GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
| AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
| EP1181550A4 (en) | METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AU2001246518A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
| AU2001267826A1 (en) | Remedies for alzheimer's disease | |
| AU2002364885A8 (en) | Alzheimer's disease model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |